Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. Among authors: loibl s. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020. PLoS One. 2020. PMID: 32841306 Free PMC article.
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M. Rody A, et al. Among authors: loibl s. Breast. 2007 Feb;16(1):86-93. doi: 10.1016/j.breast.2006.06.008. Epub 2006 Sep 28. Breast. 2007. PMID: 17010609 Clinical Trial.
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. von Minckwitz G, et al. Among authors: loibl s. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. doi: 10.1200/JCO.2008.19.6618. Epub 2009 Mar 16. J Clin Oncol. 2009. PMID: 19289619 Clinical Trial.
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G. Darb-Esfahani S, et al. Among authors: loibl s. Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Breast Cancer Res. 2009. PMID: 19758440 Free PMC article. Clinical Trial.
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer JU, Ataseven B, Weiss E, Tesch H, Gerber B, Baumann KH, Thomssen C, Breitbach GP, Ibishi S, Jackisch C, Mehta K, von Minckwitz G. Costa SD, et al. Among authors: loibl s. J Clin Oncol. 2010 Jan 1;28(1):83-91. doi: 10.1200/JCO.2009.23.5101. Epub 2009 Nov 9. J Clin Oncol. 2010. PMID: 19901111 Clinical Trial.
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. Denkert C, et al. Among authors: loibl s. J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917869 Clinical Trial.
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G. Untch M, et al. Among authors: loibl s. J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308670 Clinical Trial.
552 results